Carmustine Waymade
Alkylating chemotherapy agent (nitrosourea) for brain tumours, lymphomas, and multiple myeloma
Quick Facts About Carmustine Waymade
Key Takeaways About Carmustine Waymade
- Crosses the blood-brain barrier: One of the few chemotherapy drugs effective against central nervous system cancers due to its high lipid solubility
- Delayed myelosuppression: Bone marrow suppression typically peaks at 4-6 weeks after administration, requiring careful blood count monitoring before repeat dosing
- Cumulative pulmonary toxicity: Risk of potentially fatal pulmonary fibrosis increases significantly with cumulative doses above 1,400 mg/m²
- Hospital-only administration: Must be given as a slow IV infusion over 1-2 hours by experienced oncology professionals in a hospital setting
- Treatment cycles every 6 weeks: Due to delayed bone marrow recovery, courses should not be repeated more frequently than every 6 weeks
What Is Carmustine Waymade and What Is It Used For?
Carmustine Waymade is an alkylating chemotherapy agent belonging to the nitrosourea class, used to treat brain tumours (including glioblastoma multiforme, brainstem glioma, medulloblastoma, and astrocytoma), Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. Its unique ability to cross the blood-brain barrier makes it invaluable in neuro-oncology.
Carmustine, also known as BCNU (bis-chloroethylnitrosourea), was first synthesised in the 1960s and has been a cornerstone of chemotherapy for central nervous system (CNS) tumours for over five decades. The active substance works by alkylating and cross-linking DNA strands, which prevents cancer cells from dividing and ultimately leads to cell death. Unlike many other chemotherapy agents, carmustine is highly lipophilic (fat-soluble), allowing it to penetrate the blood-brain barrier and reach therapeutic concentrations within the cerebrospinal fluid.
Carmustine Waymade is the brand name for a formulation manufactured by Waymade Healthcare. It is presented as a powder and solvent for concentrate for solution for infusion, available in 100 mg vials. The product requires reconstitution before use and is administered exclusively as a slow intravenous infusion in hospital settings under the supervision of physicians experienced in cancer chemotherapy.
Indications for Carmustine Waymade
Carmustine Waymade is indicated for the treatment of several types of cancer, either as a single agent or in combination with other chemotherapy drugs:
- Brain tumours: Glioblastoma multiforme, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumours. Carmustine is a key component of the PCV (procarbazine, lomustine/carmustine, vincristine) regimen used for oligodendrogliomas
- Hodgkin lymphoma: Often used as part of combination chemotherapy regimens when first-line treatment has failed or as part of high-dose conditioning regimens before autologous stem cell transplantation
- Non-Hodgkin lymphoma: Used in various combination regimens, particularly the BEAM (BCNU, etoposide, cytarabine, melphalan) conditioning protocol before stem cell transplantation
- Multiple myeloma: Used in combination regimens for patients with relapsed or refractory disease
How Does Carmustine Work?
Carmustine exerts its anticancer effect through multiple mechanisms. As a bifunctional alkylating agent, it attaches alkyl groups to the DNA of cancer cells, creating inter-strand and intra-strand DNA cross-links. This prevents the DNA double helix from unwinding during replication, effectively blocking cell division. Carmustine also inhibits several key enzymes involved in DNA repair processes, including DNA polymerase, RNA polymerase, and glutathione reductase.
The drug undergoes spontaneous chemical decomposition in the body to form two reactive intermediates: a chloroethyl carbonium ion (which alkylates DNA) and an isocyanate group (which carbamoylates amino acids in proteins). This dual mechanism contributes to its broad anticancer activity but also accounts for some of its toxicity.
A particularly important property of carmustine is its ability to cross the blood-brain barrier. The drug achieves cerebrospinal fluid concentrations of approximately 15-70% of simultaneous plasma levels, a ratio that is substantially higher than most other chemotherapy agents. This makes carmustine one of the most effective systemically administered chemotherapy drugs for treating CNS malignancies.
Carmustine is listed on the WHO Model List of Essential Medicines as an important antineoplastic agent. According to the National Comprehensive Cancer Network (NCCN) guidelines, carmustine-containing regimens remain standard of care for several CNS tumour types and as conditioning therapy before haematopoietic stem cell transplantation.
What Should You Know Before Receiving Carmustine Waymade?
Before receiving carmustine, your doctor must evaluate your blood counts, lung function, liver function, and kidney function. Carmustine should not be given to patients with severe bone marrow suppression or to those who are pregnant or breastfeeding. Several drug interactions exist that may increase toxicity or reduce effectiveness.
Carmustine is a potent cytotoxic agent with significant potential for serious adverse effects. Before initiating treatment, your oncologist will conduct a thorough assessment of your overall health status and organ function. Treatment with carmustine requires careful risk-benefit analysis and ongoing monitoring throughout the course of therapy.
Contraindications
Carmustine Waymade must not be used in the following situations:
- Hypersensitivity: Known allergy to carmustine, other nitrosoureas, or any of the excipients in the formulation
- Severe bone marrow suppression: Patients with significantly reduced blood cell counts (leukopenia, thrombocytopenia) should not receive carmustine until counts have recovered
- Pregnancy and breastfeeding: Carmustine is teratogenic and embryotoxic in animal studies. It must not be used during pregnancy, and women of childbearing potential must use effective contraception during and for at least 6 months after treatment
- Breastfeeding: It is not known whether carmustine passes into human breast milk. Breastfeeding must be discontinued during treatment and for at least one week after the last dose
Warnings and Precautions
Several critical warnings apply to carmustine treatment:
Carmustine causes delayed and cumulative bone marrow suppression. Thrombocytopenia (low platelets) typically occurs around 4 weeks after administration and lasts 1-2 weeks. Leucopenia (low white blood cells) occurs at 5-6 weeks and lasts 1-2 weeks. Blood counts must be monitored weekly for at least 6 weeks after each dose. Do not give repeat courses more frequently than every 6 weeks, and only when blood counts have sufficiently recovered.
Carmustine can cause dose-related pulmonary fibrosis that may be fatal. Risk is increased with cumulative doses above 1,400 mg/m², but has been reported at lower doses. Baseline and periodic pulmonary function tests (including DLCO) are required. Patients with a baseline DLCO below 70% of predicted are at particularly high risk. Childhood exposure is associated with long-delayed pulmonary fibrosis occurring up to 17 years after treatment.
- Hepatotoxicity: Carmustine can cause reversible increases in transaminases, alkaline phosphatase, and bilirubin. Liver function should be monitored periodically
- Nephrotoxicity: Renal impairment has been reported, particularly with prolonged treatment and high cumulative doses. Kidney function should be assessed before each course
- Secondary malignancies: As with other alkylating agents, long-term use of carmustine is associated with an increased risk of secondary cancers, including acute leukaemia and myelodysplastic syndromes
- Infusion site reactions: Carmustine is a vesicant. Extravasation can cause severe tissue damage. The infusion site must be monitored carefully during administration
- Fertility: Carmustine can cause infertility in both men and women. Patients should be counselled about fertility preservation options before starting treatment
Pregnancy and Breastfeeding
Carmustine is classified as Pregnancy Category D by the FDA, meaning there is positive evidence of human foetal risk based on adverse reaction data. Animal studies have demonstrated teratogenic, embryotoxic, and fetotoxic effects. Women of childbearing potential must have a negative pregnancy test before starting treatment and use highly effective contraception during treatment and for at least 6 months after the last dose. Male patients should use contraception during treatment and for at least 3 months after the last dose.
Breastfeeding must be discontinued before starting carmustine therapy. The excretion of carmustine in human breast milk has not been studied, but given its chemical properties and mechanism of action, exposure of nursing infants could be harmful.
How Does Carmustine Waymade Interact with Other Drugs?
Carmustine interacts with several medications that may increase toxicity or reduce effectiveness. Key interactions include enhanced myelosuppression with other bone marrow-suppressing drugs, increased pulmonary toxicity with cyclophosphamide, reduced levels of phenytoin and digoxin, and potentiation of toxicity by cimetidine.
Drug interactions are a significant concern with carmustine therapy because of its potent effects on the bone marrow and other organs. Your oncologist will carefully review all medications you are taking before initiating carmustine treatment. Here are the most clinically relevant interactions:
| Interacting Drug | Effect | Severity | Clinical Action |
|---|---|---|---|
| Cimetidine | Enhances bone marrow suppression by inhibiting carmustine metabolism | Major | Avoid concomitant use; use alternative H2 antagonist |
| Phenytoin | Carmustine may reduce phenytoin serum levels, risking seizure breakthrough | Major | Monitor phenytoin levels closely; dose adjustment may be needed |
| Digoxin | Carmustine may reduce digoxin absorption and serum levels | Moderate | Monitor digoxin levels; consider dose adjustment |
| Cyclophosphamide | Additive pulmonary toxicity when used in combination | Major | Monitor pulmonary function tests; consider cumulative toxicity |
| Melphalan | Enhanced myelosuppression in BEAM conditioning regimen | Major | Used intentionally in BEAM; requires stem cell rescue |
| Live vaccines | Risk of severe or fatal infections due to immunosuppression | Major | Avoid live vaccines during and after treatment |
| Other myelosuppressive agents | Additive bone marrow suppression | Major | Monitor blood counts more frequently |
Major Interactions
The most clinically significant interaction is with cimetidine, an H2-receptor antagonist used for gastric acid suppression. Cimetidine inhibits the hepatic metabolism of carmustine, leading to increased drug levels and enhanced bone marrow toxicity. If acid suppression is needed, alternative agents such as ranitidine, famotidine, or proton pump inhibitors should be used instead.
The combination of carmustine with other myelosuppressive agents carries additive risk of severe bone marrow suppression. This is particularly important in combination chemotherapy regimens such as BEAM, where the myelosuppressive effects are intentional and managed with autologous stem cell transplantation. Outside of transplant settings, concurrent use of multiple myelosuppressive agents requires very careful monitoring.
Minor Interactions
Carmustine may reduce the absorption and effectiveness of digoxin and oral phenytoin through damage to the gastrointestinal mucosa and altered drug metabolism. Patients on these medications should have their drug levels monitored more frequently during carmustine therapy, with dose adjustments as needed to maintain therapeutic levels.
Additionally, patients should be advised to avoid alcohol during carmustine treatment, as both carmustine and alcohol can cause hepatotoxicity, and the combination may increase the risk of liver damage.
What Is the Correct Dosage of Carmustine Waymade?
The standard dose of carmustine as a single agent is 150-200 mg/m² intravenously every 6 weeks, either as a single dose or divided over 2 consecutive days (75-100 mg/m²/day). When used in combination regimens, doses are typically lower. Dosing is adjusted based on blood counts from the previous cycle.
Carmustine dosing is complex and individualised based on the patient's body surface area (BSA), blood count recovery from previous cycles, the specific cancer being treated, and whether it is used alone or in combination with other drugs. All dosing decisions should be made by experienced oncologists.
Adults
Single Agent Therapy
Standard dose: 150-200 mg/m² IV every 6 weeks
This may be given as a single infusion or divided into daily injections of 75-100 mg/m² on 2 consecutive days. The infusion should be administered over 1-2 hours. Shorter infusion times are associated with increased pain and burning at the injection site.
Combination Therapy – BEAM Regimen
Dose: 300 mg/m² IV on Day -6 (before stem cell transplant)
Used as conditioning therapy before autologous haematopoietic stem cell transplantation for lymphoma. This high-dose regimen is only administered in specialised transplant centres.
| Nadir After Prior Dose | Leucocytes (/µL) | Platelets (/µL) | Dose Adjustment |
|---|---|---|---|
| Adequate recovery | > 4,000 | > 100,000 | 100% of previous dose |
| Moderate depression | 3,000 – 3,999 | 75,000 – 99,999 | 100% of previous dose |
| Significant depression | 2,000 – 2,999 | 25,000 – 74,999 | 70% of previous dose |
| Severe depression | < 2,000 | < 25,000 | 50% of previous dose |
Children
Carmustine may be used in paediatric patients under specialist oncology supervision. Dosing in children is generally similar to adults on a mg/m² basis and is determined by the treating paediatric oncologist based on the specific protocol being used. However, special caution is required because children are at increased risk of delayed pulmonary toxicity that may not manifest until years or even decades after treatment. Long-term follow-up with periodic pulmonary function testing is essential for all paediatric patients who receive carmustine.
Elderly
Elderly patients may be more susceptible to the toxic effects of carmustine, particularly myelosuppression, pulmonary toxicity, and hepatotoxicity. Dose reductions may be necessary, and more frequent monitoring of blood counts and organ function is recommended. Renal function should be assessed before each cycle, as age-related decline in kidney function may affect drug clearance. The decision to treat elderly patients with carmustine should be based on a careful assessment of their overall fitness, comorbidities, and the expected benefit of treatment.
Missed Dose
Carmustine is administered in a hospital setting under medical supervision, so missed doses are unlikely. If a scheduled treatment cycle is delayed (for example, due to insufficient blood count recovery), your oncologist will determine the appropriate time to resume treatment based on your blood test results. Treatment should not be resumed until leucocytes are above 4,000/µL and platelets are above 100,000/µL.
Overdose
There is no specific antidote for carmustine overdose. In the event of overdose, the primary concerns are severe and prolonged bone marrow suppression, which may be life-threatening. Management is supportive and includes intensive monitoring of blood counts, administration of growth factors (G-CSF), platelet transfusions, and antimicrobial prophylaxis. Haemodialysis is unlikely to be beneficial due to the rapid decomposition of carmustine in the body (half-life approximately 15-30 minutes).
What Are the Side Effects of Carmustine Waymade?
Carmustine causes significant side effects due to its cytotoxic mechanism. The most common include delayed myelosuppression (almost all patients), nausea and vomiting, and injection site reactions. The most serious include pulmonary fibrosis, which can be fatal, and severe bone marrow suppression leading to infections and bleeding.
Like all chemotherapy agents, carmustine affects rapidly dividing normal cells in addition to cancer cells. The side effects of carmustine are well-characterised from decades of clinical use. Your oncology team will monitor you closely and provide supportive care to manage these effects. It is important to report any new symptoms promptly, as early intervention can prevent serious complications.
Very Common (>1 in 10 patients)
- Myelosuppression – delayed leucopenia and thrombocytopenia (affects nearly all patients); nadir at 4-6 weeks
- Nausea and vomiting – often begins 2-4 hours after infusion and may last 4-6 hours; preventable with antiemetics
- Injection site reactions – pain, burning, and erythema along the vein during infusion
- Flushing – facial flushing due to the alcohol solvent, occurring during or shortly after infusion
- Pulmonary infiltrates and/or fibrosis – dose-related; risk increases with cumulative doses >1,400 mg/m²
Common (1 in 10 to 1 in 100 patients)
- Hepatotoxicity – elevated transaminases, alkaline phosphatase, and bilirubin; usually reversible
- Nephrotoxicity – decreased kidney function, elevated creatinine and BUN
- Diarrhoea – may contribute to dehydration and electrolyte imbalances
- Stomatitis – mouth sores and inflammation of the oral mucosa
- Alopecia – hair loss, usually temporary and reversible after treatment ends
- Hyperpigmentation – skin darkening at the injection site or along the infused vein
Uncommon (1 in 100 to 1 in 1,000 patients)
- Encephalomyelopathy – brain and spinal cord toxicity, particularly at high doses
- Retinal haemorrhage – bleeding in the eye, reported mainly with high-dose regimens
- Neuro-retinitis – inflammation of the optic nerve and retina
- Gynecomastia – breast tissue enlargement in males
- Chest pain – non-cardiac chest discomfort
Rare (<1 in 1,000 patients)
- Secondary acute leukaemia – may develop months to years after treatment, related to cumulative alkylating agent exposure
- Myelodysplastic syndrome – bone marrow disorder that may progress to leukaemia
- Veno-occlusive disease – blockage of hepatic veins, mainly with high-dose regimens
- Allergic reactions – hypersensitivity including anaphylaxis (very rare)
Seek urgent medical attention if you develop: fever or signs of infection (as this may indicate severe neutropenia), unusual bleeding or bruising (low platelets), persistent cough or shortness of breath (pulmonary toxicity), yellowing of the skin or eyes (liver damage), or significantly reduced urine output (kidney problems). These symptoms may indicate serious complications that require immediate medical intervention.
How Should You Store Carmustine Waymade?
Unopened carmustine vials must be stored in a refrigerator at 2-8°C, protected from light. The reconstituted solution should be used within 24 hours when refrigerated or within 3 hours at room temperature. Do not use if an oily film appears in the vial, as this indicates decomposition.
Proper storage of carmustine is critical because the drug is sensitive to temperature and light. Incorrect storage can lead to decomposition, rendering the product ineffective and potentially harmful. In practice, storage is managed by the hospital pharmacy, but understanding storage requirements helps ensure the quality of the medication you receive.
- Unopened vials: Store in a refrigerator at 2-8°C. Protect from light by keeping vials in the original carton. Do not freeze
- Reconstituted solution: After reconstitution with the provided solvent, the concentrate should be further diluted and used within 24 hours when stored at 2-8°C, or within 3 hours at room temperature (up to 25°C)
- Visual inspection: Before use, the reconstituted solution should be inspected visually. It should be a clear, colourless to slightly yellow solution. Do not use if an oily film is visible on the surface, as this indicates thermal decomposition
- Disposal: Any unused product or waste material must be disposed of in accordance with local requirements for cytotoxic agents. Carmustine is hazardous and must be handled with appropriate personal protective equipment
Carmustine is unusually sensitive to temperature. If the powder appears as an oily or wet mass, or if an oily film is visible on the surface of the reconstituted solution, the product has undergone decomposition and must not be used. Vials that have been exposed to temperatures above 25°C for extended periods should be discarded even if they appear normal, as decomposition products may not always be visible.
What Does Carmustine Waymade Contain?
Each vial of Carmustine Waymade contains 100 mg of carmustine as the active ingredient. The solvent provided for reconstitution is sterile dehydrated ethanol. After reconstitution, the concentrate is further diluted with sodium chloride 0.9% or glucose 5% for intravenous infusion.
Understanding the composition of Carmustine Waymade is important for healthcare professionals to ensure safe preparation and administration, and for patients to be aware of potential excipient-related effects.
Active Ingredient
Each vial contains 100 mg of carmustine (also known as BCNU or 1,3-bis(2-chloroethyl)-1-nitrosourea). Carmustine is a white to pale yellow powder with a molecular weight of 214.05 g/mol. Its molecular formula is C5H9Cl2N3O2. The drug is highly lipid-soluble, which accounts for its ability to cross the blood-brain barrier.
Solvent and Excipients
The product is supplied with a separate vial of sterile dehydrated ethanol (3 mL) as the reconstitution solvent. This is important for several reasons:
- Carmustine has poor aqueous solubility and requires an organic solvent for initial dissolution
- The ethanol content means patients may experience flushing or a sensation of warmth during infusion
- Patients with alcohol intolerance should be informed of the ethanol content
- The ethanol may interact with certain medications, including metronidazole and disulfiram
After reconstitution in ethanol, the concentrate is further diluted with 500 mL of sodium chloride 0.9% or glucose 5% to produce the final infusion solution. The diluted solution should be administered through glass containers or polyolefin bags, as carmustine can interact with PVC infusion equipment.
Frequently Asked Questions About Carmustine Waymade
Carmustine (BCNU) is used to treat brain tumours (glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumours), Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma. It is particularly valued for its ability to cross the blood-brain barrier, making it one of the few chemotherapy drugs effective against central nervous system cancers. It is also a key component of the BEAM conditioning regimen used before autologous stem cell transplantation.
Carmustine Waymade is given as a slow intravenous infusion over 1 to 2 hours. The powder is first dissolved in the provided ethanol solvent and then further diluted with 500 mL of sodium chloride 0.9% or glucose 5%. It must be administered in a hospital setting by healthcare professionals experienced in cancer chemotherapy. The infusion must not be given too rapidly, as this increases the risk of pain at the injection site and flushing.
The most serious side effects include delayed bone marrow suppression (myelosuppression) that typically peaks at 4-6 weeks after administration, pulmonary fibrosis which can be fatal (especially at cumulative doses above 1,400 mg/m²), hepatotoxicity with elevated liver enzymes, and nephrotoxicity. Secondary malignancies including acute leukaemia and myelodysplastic syndromes have also been reported with long-term use. Regular monitoring of blood counts, pulmonary function, liver function, and kidney function is mandatory.
Yes, carmustine is one of the few chemotherapy drugs that can effectively cross the blood-brain barrier. This is due to its high lipid solubility, which allows it to penetrate into the cerebrospinal fluid at concentrations of approximately 15-70% of plasma levels. This property makes it particularly useful for treating brain tumours and central nervous system cancers where many other chemotherapy agents cannot reach therapeutic concentrations.
Carmustine causes delayed bone marrow suppression, with the lowest blood counts (nadir) typically occurring at 4-6 weeks after administration. Thrombocytopenia usually occurs around week 4 and leucopenia around week 5-6, each lasting approximately 1-2 weeks. The bone marrow needs sufficient time to recover before another dose can be safely administered. Giving doses more frequently than every 6 weeks increases the risk of severe and potentially life-threatening myelosuppression. Blood counts must be checked and confirmed as adequate before each new cycle.
Unopened carmustine vials should be stored in a refrigerator at 2-8°C, protected from light. After reconstitution, the solution should be used within 24 hours if refrigerated or within 3 hours at room temperature. Carmustine is very sensitive to temperature: if an oily film appears in the vial, it indicates decomposition, and the product should not be used. This is why proper cold-chain storage is critical for this medication.
References
- European Medicines Agency (EMA). Summary of Product Characteristics: Carmustine. European public assessment reports. Available at: www.ema.europa.eu
- World Health Organization. WHO Model List of Essential Medicines – 23rd List, 2023. Geneva: World Health Organization; 2023.
- British National Formulary (BNF). Carmustine. National Institute for Health and Care Excellence (NICE). Available at: bnf.nice.org.uk
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Central Nervous System Cancers. Version 1.2025.
- Brandes AA, Tosoni A, Franceschi E, et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2009;64(4):769-775.
- Reithmeier T, Graf E, Piroth T, et al. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors. BMC Cancer. 2010;10:30.
- Keating GM. Carmustine implant: a review in newly diagnosed high-grade glioma. Drugs. 2016;76(6):675-681.
- Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995;13(3):588-595.
- O’Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990;323(6):378-382.
- U.S. Food and Drug Administration (FDA). Prescribing Information: BiCNU (carmustine for injection). Reference ID: FDA-approved labelling.
About the Medical Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, which includes licensed physicians specialising in oncology, haematology, and clinical pharmacology. Our team follows the GRADE evidence framework and bases all content on peer-reviewed research, international treatment guidelines, and official drug information from the EMA, FDA, and WHO.
All drug information is cross-referenced with the EMA Summary of Product Characteristics, FDA prescribing information, and the British National Formulary to ensure accuracy and completeness.
iMedic receives no commercial funding from pharmaceutical companies. Our content is entirely independent, with no advertising or sponsorship influencing our editorial decisions.
This article is reviewed and updated regularly to reflect the latest clinical evidence, guideline changes, and safety communications from regulatory authorities.
Content is graded according to the GRADE framework. This article is based on Level 1A evidence from systematic reviews, randomised controlled trials, and authoritative clinical guidelines.